###### Strengths and limitations of this study

-   This is one of the few studies reporting on temporal trends in causes of death of HIV-infected adults in sub-Saharan Africa and reporting causes of death in individuals on antiretroviral treatment for longer than 1 year.

-   The study clinic has an elaborate network of care provision that involves community healthcare workers who frequently make home visits and make notes in the clinic file. Therefore, despite the retrospective nature of the study, the occurrence of a death and a probable cause of death could be assessed in most cases.

-   The lack of data on the whole clinic population forced us to estimate the mortality rate and prevented us from relating the changes observed in our cohort of deaths to changes in the clinic population.

-   Chart review is known to have a relatively poor accuracy in HIV-infected individuals when compared with the gold standard of complete histological autopsy. This is a common problem of all studies that use chart review to establish the cause of death. Since autopsies are not widely available, innovative and accurate alternatives are needed.

Background {#s1}
==========

Over the past decade, the landscape of HIV care and treatment in sub-Saharan Africa (SSA) has changed tremendously. Testing and counselling services have been scaled up, antiretroviral therapy (ART) has become more widely available and guidelines suggesting initiating ART at higher CD4 counts have been issued.[@R1] [@R2] In Uganda, the number of HIV-infected people on ART between 2001 and 2012 increased from scarcely any to almost 440 000.[@R2] Moreover, improved diagnostic tests for common opportunistic infections such as tuberculosis (TB) are being implemented.[@R3] [@R4] All of these measures have resulted in a decline in mortality among HIV-infected individuals throughout SSA.[@R2] [@R5]

In reports to date, the majority of deaths among HIV-infected adults in SSA have been secondary to HIV-related infections and malignancies.[@R8] [@R9] These studies included mainly untreated HIV-infected patients or patients recently started on ART. Studies including patients on ART for more than 1 year have been scarce. With the longer survival of HIV-infected individuals, one may expect a transition in causes of morbidity and mortality.[@R10] Changes in socioeconomic development, lifestyle and dietary intake impact the causes of death in the population as a whole, and also that of HIV-infected individuals.[@R11] ART-related toxicity and (low-level) chronic inflammation are additional factors that may influence the cause of death of HIV-infected patients. All of these factors can induce a shift towards causes of death that are not directly related to the immunodeficiency caused by HIV. In countries where ART has been available for a longer time, such a shift is already seen and hepatic diseases, cardiovascular diseases and non-AIDS malignancies have become common causes of death.[@R12] Awareness of such a changing pattern in the African setting is of importance for patient care and resource allocation. Current HIV care in SSA is largely focused on management of opportunistic co-infections. If non-infectious chronic medical conditions become increasingly responsible for death among HIV-infected individuals, a shift in focus would be needed.[@R15]

We evaluated all-cause mortality in HIV-infected adults who attended an urban HIV treatment facility in Kampala, Uganda. We retrospectively studied the antemortem characteristics, the clinical course of the deceased and the causes of death since the start of the clinic in 2001 until 2012 to see if any temporal trends in causes of death could be observed. Moreover, we report the causes of death of patients on ART for more than 1 year.

Methods {#s2}
=======

Study setting and population {#s2a}
----------------------------

We conducted a retrospective study at the Reach Out Mbuya Parish HIV/AIDS Initiative (ROM) in Kampala. ROM\'s HIV treatment programme has been described in detail previously.[@R16] [@R17] In brief, ROM has provided free individual support services and community programmes to HIV-infected patients living in the urban slums that surround the parish since May 2001. Free ART first became available in June 2003 through research-based clinics and individual sponsorships. In March 2004, ROM was the first programme to initiate ART through the United States President\'s Emergency Plan for AIDS Relief. However, the demand was greater than the supply and ART initiation was based on the principle to serve those with the lowest CD4 cell count first. ART eligibility was based on the WHO guidelines adopted for use through the Uganda National ART guidelines and subsequently followed the evolving recommendations to initiate ART at a higher CD4 cell count.

CD4 count measurement has been available since 2004, but viral load measurement was never routinely available. Nurse clinicians provide most of the clinic care. They are trained to work according to the national guidelines and can request for additional testing when indicated. They consult or refer to the medical officer when needed. Patients visit the clinic at intervals from every 2 weeks to once per 3 months depending on their treatment status. Moreover, community healthcare workers (CHWs), trained peers who support each patient and maintain a close relation with the patient, conduct home visits at intervals from daily to once per 3 months based on the needs of the specific patient. Bedridden or hospitalised patients are visited weekly by CHWs. Any relevant medical information obtained during their visits is noted in the clinic file.

Registration and tracing of patients {#s2b}
------------------------------------

In the clinic registration system, patients are classified as 'active', 'dead', 'lost to follow-up (LTFU)' or 'transferred out'. In case a patient misses the appointment, the CHW makes a home visit to ascertain the reason for the missed appointment. Until October 2008, missed appointments were identified using a handwritten register and it could take up to 1 month after the missed appointment that a CHW visit was made. Since then, an electronic medical record system has been installed that identifies missed appointments the same day and allows for home visits by the CHW within 24 h. A patient is classified as 'dead' if the clinic or CHW is informed about the patient's death. If a patient misses clinic appointments for \>90 days, the CHW is unable to gather additional information, he/she is classified as 'LTFU'. Owing to the efficient community network and the frequent home visits, the clinic is generally well informed about the health status of its patients and reliable information about the circumstances of a death can be collected.

Mortality audit {#s2c}
---------------

In March 2013, ROM established a database including all patients who had died since the start of the clinic in May 2001. A trained administrative assistant extracted the following information from the clinic file of each patient known to have died: date of HIV diagnosis; date of registration; CD4 count at registration, at its lowest value, and the latest CD4 prior to death; if the patient was started on ART, the date ART was started and the regimen; the date of death; and the last weight and the height recorded prior to death. Two experienced medical doctors (LE and DK) then reviewed the clinic file and summarised the clinically relevant events preceding the death. In case of any inconsistency in the database, these doctors would review the patients' clinic file and adjust the information accordingly.

Assigning the cause of death {#s2d}
----------------------------

Two study team doctors (DK and JAC) independently reviewed the database. A cause of death was assigned to each adult patient based on a listing of predefined causes of death, which was derived from the global burden of disease listing.[@R18] Patients below 18 years of age or with an unknown death date were excluded. When no specific cause of death could be assigned, but the cause of death was considered to be related to a communicable disease, for example, because of the presence of fever, the category 'communicable disease unspecified' was assigned, and the organ system involved (respiratory, central nervous system, gastrointestinal, other or unclear) indicated. This was the same for 'non-communicable diseases unspecified'. HIV as a cause of death was assigned only to patients with a CD4 count below 100 cells/mm^3^ in the 6 months preceding death without the start of ART and no apparent other cause of death. Two causes of death could be assigned to one patient if two diseases were thought to have contributed equally to a patient\'s death (eg, pulmonary TB and diabetic ketoacidosis). In cases where no distinction could be made between a communicable or non-communicable cause of death, the category 'unknown' was assigned. The cause-of-death listings of both doctors were compared, and in case of a discrepancy, it was discussed with a third doctor (RC) to assign a final consensus cause of death.

Outcomes and statistical methods {#s2e}
--------------------------------

Causes of death were divided into four categories: (1) communicable conditions and AIDS-defining malignancies, (2) chronic non-communicable conditions, (3) other non-communicable conditions which included pregnancy-related death, external causes (accidents, suicide, assault) and postoperative death and (4) unknown.

Proportions are reported with a Wilson 95% CI and medians with an IQR. When reporting CD4 counts, unless otherwise indicated, only results that were obtained within 6 months of the outcome of interest were included. For comparison of non-normally distributed variables, two-sided Wilcoxon rank sum test was performed. A p value ≤0.05 was considered statistically significant. Person years of follow-up (PYFU) for the whole clinic population were not available, but were estimated as follows: each patient in care on 31 December of the previous year was calculated as 1 PYFU, all new registrations during the year were calculated as 0.5 PYFU and all deaths during the year were calculated as 0.5 PYFU. For example, for 2003 we calculated 525 PYFU+0.5(860−525)+0.5×126=756 PYFU in total. We evaluated trends in the proportion of cause-of-death categories over time by using multinomial logistic regression with year of death as a continuous independent variable. We evaluated trends in individual diseases over time by using logistic regression with year of death as a continuous independent variable. Each individual disease was tested separately against the total of all other categories.

Results {#s3}
=======

On 1 May 2001, ROM started with 10 HIV-infected patients. By 31 December 2012, 4784 patients were in active care, of whom 92% were ≥18 years. In total, 1249 patients were classified 'dead' over the years, and of these, 1128 (90%) clinic files were retrieved and entered into the database. None of the files from the 20 deaths that occurred in 2001 were retrievable. Therefore, our study period covers 1 January 2002 to 31 December 2012.

After reviewing the database, the study team excluded 100 deaths from further analysis because they were aged \<18 years (n=43) or their date of death was unknown (n=57). Hence, we analysed the data of 1028 deaths. At least one CD4 count was available for 68% of patients who died after 2004.

Characteristics of the deceased study participants {#s3a}
--------------------------------------------------

Over time, the estimated mortality rate dropped from 21.86 deaths/100 PYFU in 2002 to 1.75/100 PYFU in 2012. The mortality rate dropped mainly in the category 'communicable condition and/or AIDS-defining malignancy', from 18.3/100 PYFU in 2002 to 1.18/100 PYFU in 2012 ([table 1](#BMJOPEN2015008718TB1){ref-type="table"} and [figure 1](#BMJOPEN2015008718F1){ref-type="fig"}).

###### 

Characteristics of the deceased patients per death year

                                                      2002           2003            2004                2005                2006                 2007                 2008                 2009                 2010                 2011                 2012                 Total
  --------------------------------------------------- -------------- --------------- ------------------- ------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
  Adults in active care\*                             525            860             1452                1892                2178                 2724†                2590                 3250†                3403                 3557                 4353                 --
  Included deaths                                     80             126             118                 111                 103                  95                   97                   62                   76                   90                   70                   1028
  Estimated PYFU                                      366            756             1215                1728                2087                 2409                 2616                 2807                 3221                 3525                 3990                 --
  Mortality rate/100 PYFU                             21.86          16.67           9.71                6.42                4.94                 3.94                 3.71                 2.21                 2.36                 2.55                 1.75                 --
  Median age (IQR)                                    32 (28--37)    35 (30--40)     34 (29--42)         36 (30--44)         36 (29--42)          38 (32--45)          36 (30--41)          36 (30--41)          36 (28--45)          39 (30--45)          39 (31--45)          36 (30--42)
  Females n (%)                                       53 (66)        82 (65)         69 (58)             72 (65)             64 (62)              53 (56)              51 (53)              40 (65)              38 (50)              41 (46)              34 (49)              597 (58)
  Median weight in kg (IQR)                           50 (42--56)    50 (44--57)     49 (43--55)         49 (43--55)         50 (44--56)          50 (42--55)          52 (45--60)          49 (44--55)          50 (44--56)          54 (45--62)          52 (45--60)          51 (44--57)
  Median BMI (IQR)                                    --             --              --                  --                  --‡                  18.0 (16.1--20.1)    18.8 (16.9--22.0)    19.0 (17.6--21.6)    18.5 (16.6--21)      19.7 (17.6--21.8)    18.8 (17.1--21.0)    18.9 (17--21.6)
  Median duration from registration to death (IQR)§   90 (53--203)   162 (89--307)   155 (80--291)       170 (62--448)       144 (58--393)        128 (41--430)        167 (67--789)        271 (68--1193)       170 (53--712)        176 (59--1758)       186 (61--774)        158 (61--420)
  Median CD4 at registration (IQR)                    --‡            --‡             49 (12--129) n=87   90 (25--232) n=98   127 (22--253) n=85   144 (34--304) n=73   119 (33--335) n=79   171 (60--390) n=54   100 (18--290) n=69   124 (35--268) n=83   81 (26--285) n=67    105 (25--265) n=70
  Median CD4 in 6 months prior to death (IQR)         --‡            --‡             49 (12--121) n=73   74 (16--202) n=80   56 (22--207) n=61    93 (17--191) n=54    130 (36--275) n=64   132 (47--351) n=45   93 (13--245) n=53    180 (35--290) n=71   105 (27--290) n=55   90 (22--237) n=563
  On ART n (%)                                        --             9 (7)           48 (41)             45 (41)             45 (44)              37 (39)              44 (45)              31 (50)              38 (50)              55 (61)              43 (61)              395 (38)
  Median duration start ART---death (IQR)§            --             31 (18--33)     61 (37--119)        86 (42--312)        142 (43--279)        93 (43--392)         144 (49--843)        212 (39--1077)       201 (44--1109)       722 (77--1501)       474 (104--1118)      142 (47--555)
  Start ART \<3 month n (%)                           --             8 (89)          34 (71)             24 (53)             17 (38)              18 (49)              17 (39)              11 (35)              11 (29)              16 (29)              8 (19)               164 (42)
  Start ART \<6 month n (%)                           --             9 (100)         42 (88)             26 (58)             29 (64)              24 (65)              23 (52)              13 (42)              19 (50)              20 (36)              15 (35)              220 (56)
  Start ART\>12 month n (%)                           --             --              --                  7 (16)              10 (22)              10 (27)              16 (36)              14 (45)              14 (37)              33 (60)              23 (53)              127 (32)

\*On 31 December of each year.

†Including children.

‡\<7 Observations.

§Duration in days.

ART, antiretroviral therapy; BMI, body mass index; n, absolute number; PYFU, person years of follow-up.

![Estimated mortality rates per category per death year PYFU (NC, non-communicable condition; PYFU, person years of follow-up).](bmjopen2015008718f01){#BMJOPEN2015008718F1}

The median age at registration of all deceased was 36 years (IQR 30--42), 58% were female, the median duration between registration and death was 158 days (IQR 61--420), and 35% of all deaths occurred within 3 months after registration and 54% within 6 months ([table 1](#BMJOPEN2015008718TB1){ref-type="table"}). The median CD4 count prior to death was 90 cells/mm^3^ (IQR 22--237). Thirty-eight per cent (n=395) of deceased were on ART, and of these 42% died within the first 3 months of ART, 56% in the first 6 months and 68% within the first year. The median CD4 count in the 6 months prior to death stratified by year of death increased from 49 cells/mm^3^ in 2004 to 132 cells/mm^3^ in 2009. After 2010, it varied between 93 and 180 cells/mm^3^ ([table 1](#BMJOPEN2015008718TB1){ref-type="table"}). The proportion of deceased patients on ART steadily increased from 41% in 2004 to 61% in 2012. The median duration between the start of ART and death was 61 days (IQR 37--119) in 2004, then increased to a maximum of 722 days (IQR 77--1501) in 2011 and decreased again to 474 days (IQR 104--1118) in 2012.

Causes of death over time {#s3b}
-------------------------

Of the 1028 deceased, 784 (76%, 95% CI 74% to 79%) died of a 'communicable condition or AIDS-defining malignancy', 48 (5%, 95% CI 4% to 7%) of a 'chronic non-communicable condition' and 29 (3%, 95% CI 2% to 4%) of an 'other non-communicable condition'. The remaining patients died of two 'communicable conditions and/or AIDS-defining malignancies' (n=47; 5%, 95% CI 3% to 6%) or a combination including at least one 'communicable condition or AIDS-defining malignancy' and one 'chronic non-communicable condition' (n=17; 2%, 95% CI 1% to 3%). For 103 patients (11%, 95% CI 9% to 13%), no cause of death could be determined.

Over time, the causes of death changed significantly (p\<0.01). The proportion of deaths from communicable conditions and AIDS-defining malignancies decreased, from 84% (95% CI 74% to 90%) in 2002 to 64% (95% CI 53% to 74%) in 2012. All other categories increased over time: death from chronic non-communicable conditions increased from 1% (95% CI 0% to 7%) in 2002 to 7% (95% CI 3% to 16%) in 2012, death from other non-communicable conditions from 1% (95% CI 0% to 7%) in 2002 to 7% (95% CI 3% to 16%) in 2012, death from a combination of communicable and non-communicable conditions from 0% in 2002 to 6% (95% CI 2% to 14%) in 2012 and death from an unknown cause from 1% (95% CI 0% to 7%) in 2002 to 6% (95% CI 2% to 14%) ([table 2](#BMJOPEN2015008718TB2){ref-type="table"} and [figure 2](#BMJOPEN2015008718F2){ref-type="fig"}).

###### 

Causes of death per death year

                                          2002      2003      2004      2005      2006      2007      2008      2009      2010      2011      2012      Total
  --------------------------------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- -----------
  **Communicable**                                                                                                                                      
   HIV                                    --        --        6 (5)     5 (5)     4 (4)     1 (1)     3 (3)     5 (8)     3 (4)     4 (4)     4 (6)     35 (3)
   Tuberculosis                           34 (43)   68 (54)   46 (39)   37 (33)   26 (25)   26 (27)   33 (34)   15 (24)   19 (25)   24 (27)   19 (27)   347 (34)
   Diarrhoeal disease                     2 (3)     4 (3)     3 (3)     2 (2)     3 (3)     3 (3)     2 (2)     2 (3)     1 (1)     2 (2)     --        24 (2)
   Respiratory tract infection            --        --        --        --        --        --        1 (1)     1 (2)     2 (3)     1 (1)     2 (3)     7 (1)
   Meningitis                             --        6 (5)     8 (7)     6 (5)     9 (9)     8 (8)     5 (5)     4 (6)     2 (3)     2 (2)     2 (3)     52 (5)\*
   Malaria                                1 (1)     --        --        --        --        2 (2)     --        --        3 (4)     3 (3)     --        9 (1)
   Kaposi\'s sarcoma                      3 (4)     8 (6)     9 (8)     10 (9)    3 (3)     10 (11)   9 (9)     3 (5)     2 (3)     5 (6)     --        62 (6)
   Other AIDS malignancy                  --        --        --        --        1 (1)     --        1 (1)     1 (2)     --        --        1 (1)     4 (\<0.5)
   Infection n.s.                         14 (18)   12 (10)   23 (19)   19 (17)   18 (17)   19 (10)   18 (19)   9 (15)    12 (16)   12 (13)   13 (19)   169 (16)
   Infection with respiratory symptoms    7 (9)     10 (8)    13 (11)   15 (14)   10 (10)   12 (13)   9 (9)     5 (8)     6 (8)     5 (6)     3 (4)     95 (9)
   Infection with CNS symptoms            4 (5)     11 (9)    8 (7)     5 (5)     8 (8)     3 (3)     2 (2)     3 (5)     4 (5)     2 (2)     3 (4)     53 (5)
   Infection with GI symptoms             1 (1)     1 (1)     1 (1)     5 (5)     5 (5)     2 (2)     2 (2)     --        2 (3)     2 (2)     3 (4)     24 (2)
   Other communicable specified           1 (1)     --        --        1 (1)     2 (2)     3 (3)     2 (2)     2 (3)     2 (3)     1 (1)     1 (1)     15 (1)
  **Chronic NC**                                                                                                                                        
   Non-AIDS-defining malignancy           --        --        1 (1)     1 (1)     1 (1)     1 (1)     2 (2)     2 (3)     2 (3)     6 (7)     1 (1)     17 (2)†
   Cardiovascular disease                 1 (1)     --        --        1 (1)     --        2 (2)     2 (2)     2 (3)     1 (1)     2 (2)     1 (1)     12 (1)
   Cerebrovascular event                  --        --        --        2 (2)     --        --        --        --        --        --        1 (1)     3 (\<0.5)
   Chronic respiratory disease            --        --        --        1 (1)     1 (1)     --        --        --        --        --        --        2 (\<0.5)
   GI and hepatic disease                 --        --        --        1 (1)     1 (1)     1 (1)     2 (2)     1 (2)     4 (5)     1 (1)     --        11 (1)‡
   Neurological or psychiatric disorder   --        --        1 (1)     --        --        --        1 (1)     --        --        --        1 (1)     3 (\<0.5)
   Diabetes                               --        --        1 (1)     --        --        1 (1)     1 (1)     1 (2)     1 (1)     --        3 (4)     8 (1)
   Chronic renal disease                  --        --        --        --        --        --        --        --        --        3 (3)     1 (1)     4 (\<0.5)
   Chronic alcohol abuse                  --        --        1 (1)     --        1 (1)     1 (1)     --        --        --        1 (1)     1 (1)     5 (\<0.5)
  **Other NC**                                                                                                                                          
   Pregnancy-related condition            --        --        --        1 (1)     --        --        1 (1)     1 (2)     --        --        1 (1)     4 (\<0.5)
   Accidents, suicide, assault            --        --        --        --        --        --        1 (1)     --        3 (4)     10 (11)   2 (3)     16 (2)
   Postoperative death                    --        --        --        --        --        --        --        --        --        2 (2)     --        2 (\<0.5)
   Pulmonary embolus                      1 (1)     --        --        1 (1)     --        --        --        --        --        --        --        2 (\<0.5)
   Other condition n.s.                   --        --        --        1 (1)     --        --        --        1 (2)     1 (1)     --        2 (3)     5 (\<0.5)

\*Confirmed cryptococcal meningitis caused death in 2% (n=24). †Consisting of malignancies of the oesophagus (n=5), breast (n=4), liver (n=1), larynx (n=1), sarcoma (n=1), brain (n=1), unknown primary origin (n=3). ‡Consisting of liver failure (n=8), upper GI bleed (n=2), cholangitis (n=1), pancreatitis (n=1).

CNS, central nervous system; GI, gastrointestinal; NC, non-communicable condition; n.s., non-specified.

![Cause of death per category per death year. \*Patients who died from a combination of 'communicable conditions and AIDS-defining malignancies' and 'chronic non-communicable conditions'.](bmjopen2015008718f02){#BMJOPEN2015008718F2}

Overall, the main cause of death was TB, which was identified in 34% (95% CI 31% to 37%) of the 1028 deceased ([table 2](#BMJOPEN2015008718TB2){ref-type="table"}). There was a significant decrease in TB as cause of death over time from 43% (95% CI 32% to 53%) in 2002 to a steady proportion of approximately 25% from 2006 onwards (p\<0.01). In total, 70% (95% CI 64% to 74%) of the TB cases were on anti-TB treatment. None of the other 'communicable conditions and AIDS-defining malignancies' showed a significant trend in time.

Chronic medical conditions were identified in 6% (95% CI 5% to 8%) of deaths overall. The main chronic non-communicable cause of death was non-AIDS-defining malignancy, which showed a prevalence ranging from 1% to 7% over the years. Oesophageal and breast cancer were the most frequent occurring non-AIDS-related malignancies. Accidents, suicide and assault were the main 'other non-communicable condition' and caused death in 2% (95% CI 1% to 3%).

Cause of death in patients on ART {#s3c}
---------------------------------

In total, 395 patients died while on ART: 268 (68%) within 1 year of starting ART and 127 (32%) while on ART for longer than 1 year. The median CD4 count before death was 56 cells/mm^3^ (IQR 14--134) in those dying within 1 year of ART compared with 229 cells/mm^3^ (IQR 145--359) in those dying while on ART for longer than 1 year (p\<0.01).

Of the 268 patients who died within 1 year of ART initiation, 208 (78%, 95% CI 72% to 82%) died of a 'communicable condition or AIDS-defining malignancy', 8 (3%, 95% CI 2% to 6%) of a 'chronic non-communicable condition', 3 (1%, 95% CI 0% to 3%) of an 'other non-communicable condition', 29 (11%, 95% CI 8% to 15%) of two 'communicable conditions and/or AIDS-defining malignancies' and 3 (1%, 95% CI 0% to 3%) of a combination of a 'communicable condition or AIDS-defining malignancy' and a 'chronic non-communicable condition'. In 17 deceased patients (6%, 95% CI 4% to 10%), no cause of death was identified. The main causes of death were TB (32%, 95% CI 26% to 38%), unspecified infection (19%, 95% CI 15% to 24%), infection with respiratory symptoms (12%, 95% CI 9% to 16%) and Kaposi sarcoma (11%, 95% CI 8% to 15%) ([table 3](#BMJOPEN2015008718TB3){ref-type="table"}).

###### 

Causes of death in deceased on ART

                                          On ART\<1 year (n=268) N (%, 95% CI)   On ART\>1 year (n=127) N (%, 95% CI)
  --------------------------------------- -------------------------------------- --------------------------------------
  **Unknown**                             17 (6, 4 to 10)                        22 (17, 12 to 25)
  **Communicable**                                                               
   HIV                                    7 (3, 1 to 5)                          1 (1, 0 to 4)
   Tuberculosis                           85 (32, 26 to 38)                      18 (14, 9 to 21)
   Diarrhoeal disease                     7 (3, 1 to 5)                          --
   Respiratory tract infection            2 (1, 0 to 3)                          1 (1, 0 to 5)
   Meningitis                             20 (7, 5 to 11)                        8 (8, 4 to 14)
   Malaria                                5 (2, 1 to 4)                          3 (3, 1 to 8)
   Kaposi\'s sarcoma                      29 (11, 8 to 15)                       4 (4, 1 to 9)
   Other AIDS-defining malignancy         --                                     3 (3, 1 to 8)
   Infection n.s.                         51 (19, 15 to 24)                      19 (18, 12 to 27)
   Infection with respiratory symptoms    32 (12, 9 to 16)                       7 (7, 3 to 13)
   Infection with CNS symptoms            16 (6, 4 to 9)                         7 (7, 3 to 13)
   Infection with GI symptoms             9 (3, 2 to 6)                          2 (2, 1 to 7)
   Other communicable specified           5 (2, 1 to 4)                          3 (3, 1 to 8)
  **Chronic NC**                                                                 
   Non-AIDS-defining malignancy           1 (0, 0 to 2)                          9 (9, 5 to 15)
   Cardiovascular disease                 4 (1, 1 to 4)                          5 (5, 2 to 11)
   Chronic respiratory disease            1 (0, 0 to 2)                          --
   Cerebrovascular event                  --                                     1 (1, 0 to 5)
   GI and hepatic disease                 2 (1, 0 to 3)                          1 (1, 0 to 5)
   Neurological or psychiatric disorder   1 (0, 0 to 2)                          1 (1, 0 to 5)
   Diabetes                               2 (1, 0 to 3)                          5 (5, 2 to 11)
   Chronic renal disease                  --                                     3 (3, 1 to 8)
  **Other NC**                                                                   
   Pregnancy-related condition            3 (1, 0 to 3)                          1 (1, 0 to 5)
   Accidents, suicide, assault            --                                     10 (10, 5 to 17)
   Postoperative death                    --                                     1 (1, 0 to 5)
   Other condition n.s.                   --                                     3 (3, 1 to 8)

ART, antiretroviral therapy; CNS, central nervous system; GI, gastrointestinal; NC, non-communicable condition; n.s., non-specified.

Of the 127 patients who died while on ART for \>1 year, 62 (49%, 95% CI 40% to 57%) died of a 'communicable condition or AIDS-defining malignancy', 18 (14%, 95% CI 9% to 21%) of a 'chronic non-communicable condition', 15 (12%, 95% CI 7% to 19%) of an 'other non-communicable condition', 3 (2%, 95% CI 0% to 7%) of two 'communicable conditions and/or AIDS-defining malignancies' and 7 (6%, 95% CI 3% to 11%) of a combination of a 'communicable condition or AIDS-defining malignancy' and a 'chronic non-communicable condition'. In 22 deceased patients (17%, 95% CI 12% to 25%), no cause of death was identified. The main causes of death were unspecified infection (18%, 95% CI 12% to 27%), TB (14%, 95% CI 9% to 21%), accident, suicide and assault (10%, 95% CI 5% to 17%), malignancies (9%, 95% CI 5% to 15%) and meningitis (8%, 95% CI 4% to 14%) ([table 3](#BMJOPEN2015008718TB3){ref-type="table"}).

Discussion {#s4}
==========

In this urban HIV treatment clinic, we observed a steep decline in mortality rate over time, which was caused mainly by a decline in mortality secondary to communicable conditions and AIDS-defining malignancies. A decreasing proportion of patients died of communicable conditions and AIDS-defining malignancies and an increasing proportion died from non-communicable diseases, chronic or non-chronic, or a combination of communicable and non-communicable diseases. Nevertheless, communicable conditions and AIDS-defining malignancies continued to be responsible for the vast majority of deaths, with TB as the main cause of death.

Mortality in HIV-infected individuals has decreased since access to ART has improved. Several other changes in the care and treatment of HIV-infected individuals have occurred over time and have impacted mortality rates. These include joint TB and HIV interventions, earlier initiation of ART and the use of prophylactic treatment for common opportunistic infections among others.[@R2]

On a population level, a decreased mortality from HIV-related causes and a relative increase in non-communicable causes of death have been reported from several SSA settings.[@R19] [@R20] Until now, studies from SSA looking in more detail at the causes of death of HIV-infected individuals have focused on mortality in untreated patients or patients who recently started ART. In these patients, the vast majority of deaths are HIV related.[@R8] [@R21] Information on causes of death in patients on ART beyond 1 year is scarce. Our findings among patients on ART for more than 1 year suggest that within this group increasing mortality from non-communicable conditions is evident. Non-AIDS malignancies, mainly breast and oesophageal cancer, cardiovascular diseases and diabetes, were the most frequent non-communicable conditions. A study that included 37 hospitalised HIV-infected patients who died while on ART for more than 12 months reported non-communicable conditions as the cause of death in 30%.[@R22] So far, HIV care and treatment efforts have focused mainly on (semi)acute services. With an increasing number of HIV-infected individuals on long-term ART, the incidence of chronic non-communicable conditions will increase.[@R23] This requires a reassessment of the traditional HIV services.

In our study, a high proportion of deaths continued to be due to communicable conditions and AIDS-defining malignancies, even in the recent years. When analysing the characteristics of the patients who died over time, the median CD4 count in the 6 months prior to death was below 200 cells/mm^3^ in each of the studied years and approximately half of all patients died within 6 months after registration at the clinic. This indicates that many patients who died, even in the recent years, presented to our clinic at a late stage with low CD4 counts and advanced HIV infection. Such patients have a high mortality risk and die almost exclusively of communicable HIV-related conditions.[@R24] Recommendations on how to treat this specific group have changed between 2002 and now. The most important change has been to start ART as soon as possible, except in case of cryptococcal or TB meningitis.[@R28] [@R29] This strategy has been shown to decrease mortality.[@R30] [@R31] However, other strategies to prevent late presentation with advanced immunosuppression also need implementation. These include timely detection of HIV infections and adequate linkage to HIV care.

TB caused death in 35% of patients and was clearly the main cause of death. This is in line with the findings of others, who have shown the major contribution of TB to death in the African HIV population.[@R9] [@R21] We found 70% of patients with TB to be on anti-TB treatment. However, this number needs to be interpreted with caution, because being on anti-TB treatment was used as a criterion to assign TB as a cause of death. The category 'unspecified infection with respiratory complaints' did not include patients on TB treatment but will most likely contain a high proportion of clinically undiagnosed TB cases. Large changes are taking place in SSA in the field of TB diagnostics. The Xpert MTB/RIF is increasingly being implemented and has shown relatively high sensitivity in HIV-infected patients and the urinary lipoarabinomannan lateral flow assay shows promising results in severely immunosuppressed HIV-infected patients.[@R4] [@R32] If and how these novel diagnostic modalities will affect TB-related mortality remains to be fully determined.[@R36]

Our study has several shortcomings. Causes of death based on chart review are known to have a relatively poor accuracy in HIV-infected individuals when compared with the gold standard of complete histological autopsy.[@R9] [@R37] [@R38] This is a common problem of all studies that use chart review or verbal autopsy procedures. Moreover, we did not have information on the clinic population as a whole, which forced us to estimate the number of PYFU and prevented us from relating the changes observed in our cohort of deaths to changes in the clinic population. We based the cause of death on information derived from the clinic file. Under-reporting of non-communicable conditions due to lack of awareness or diagnostic modalities may have occurred. Since no information can be ascertained for patients LTFU, deaths occurring in this group were not taken into account. Death causes in those LTFU might differ from the death causes of the patients we included. Lastly, viral loads were not routinely assessed and we could not establish what proportion of death was attributable to virologic failure.

In conclusion, over a time period of 11 years, we observed a decrease in the proportion of deaths from communicable conditions and AIDS-defining malignancies and an increase in the proportion of deaths due to non-communicable conditions. With a growing population on ART, one may assume that changes will continue in this direction. However, increased patient loads within clinics may lead to loss of quality of adherence counselling and support. Also, limited access to treatment monitoring tools such as HIV viral load and increasing first-line ART resistance could act against this trend and result in a continuing high proportion of HIV-related mortality.[@R39] Therefore, ongoing monitoring of cause of death is warranted. Innovative and accurate methods to assess this on a population level are needed, since complete autopsies are not widely available. Moreover, despite the decrease, communicable conditions and AIDS-defining malignancies, particularly TB, continue to be responsible for the majority of deaths. This confirms a critical need for better screening strategies, accurate diagnostics and effective prevention strategies for TB and other common opportunistic infections.
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